All of the mAbs neutralize the infection in different combinations of HCMV strains and target cells , with a potency ~20 fold higher than that of the HCMV hyperimmune globulins ,
currently used in transplant recipients .
All of the mAbs neutralize the infection in different combinations of HCMV strains and target cells , with a potency ~20 fold higher than that of the HCMV hyperimmune globulins , currently used in transplant recipients .
All of the mAbs neutralize the infection in different combinations of HCMV strains and target cells , with a potency ~20 fold higher than that of the HCMV hyperimmune globulins , currently used in transplant recipients .